Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Cash & Equivalents (2016 - 2025)

Avalo Therapeutics filings provide 12 years of Cash & Equivalents readings, the most recent being $15.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 83363.16% to $15.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $15.9 million, a 83363.16% increase, with the full-year FY2025 number at $15.9 million, up 83363.16% from a year prior.
  • Cash & Equivalents hit $15.9 million in Q4 2025 for Avalo Therapeutics, up from $90000.0 in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $125.0 million in Q1 2025 to a low of $14000.0 in Q2 2022.
  • Median Cash & Equivalents over the past 5 years was $8.8 million (2023), compared with a mean of $29.2 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 174784.13% in 2024 and later tumbled 99.98% in 2025.
  • Avalo Therapeutics' Cash & Equivalents stood at $51000.0 in 2021, then plummeted by 70.59% to $15000.0 in 2022, then skyrocketed by 49333.33% to $7.4 million in 2023, then plummeted by 99.74% to $19000.0 in 2024, then skyrocketed by 83363.16% to $15.9 million in 2025.
  • The last three reported values for Cash & Equivalents were $15.9 million (Q4 2025), $90000.0 (Q3 2025), and $20000.0 (Q2 2025) per Business Quant data.